Shares of Insmed Inc. (INSM) are up an impressive 130% at $51 in pre-market trading Tuesday, thanks to positive topline results from the ASPEN study.
ASPEN is a phase III trial of the company's investigational drug Brensocatib in patients with non-cystic fibrosis bronchiectasis.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com